Valuation: DaShenLin Pharmaceutical Group Co., Ltd.

Capitalization 2.23TCr 320.21Cr 273.78Cr 254.15Cr 238.35Cr 442.19Cr 29TCr 473.5Cr 2.92TCr 1.15TCr 14TCr 1.2TCr 1.18TCr 51TCr P/E ratio 2025 *
19x
P/E ratio 2026 * 15.8x
Enterprise value 2.05TCr 293.85Cr 251.24Cr 233.22Cr 218.73Cr 405.79Cr 27TCr 434.51Cr 2.68TCr 1.06TCr 13TCr 1.1TCr 1.08TCr 46TCr EV / Sales 2025 *
0.74x
EV / Sales 2026 * 0.64x
Free-Float
33.49%
Yield 2025 *
2.87%
Yield 2026 * 3.39%
More valuation ratios * Estimated data
Dynamic Chart
30/25/30 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
28/25/28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25/25/25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25/25/25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
15/24/15 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
20/24/20 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
18/24/18 DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million. CI
30/24/30 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
03/24/03 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
07/24/07 DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024. CI
28/24/28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
28/24/28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
18/24/18 Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares MT
More news
1 day+0.77%
1 week+4.48%
Current month+11.12%
1 month+6.12%
3 months+4.87%
6 months+16.20%
Current year+11.12%
More quotes
1 week 18.68
Extreme 18.68
19.99
1 month 17.41
Extreme 17.41
19.99
Current year 17.41
Extreme 17.41
19.99
1 year 13.61
Extreme 13.61
19.99
3 years 11.92
Extreme 11.92
33.58
5 years 11.92
Extreme 11.92
61.63
10 years 11
Extreme 11.0028
61.63
More quotes
Manager TitleAgeSince
Chief Executive Officer 44 28/02/2019
Director of Finance/CFO 44 10/05/2018
Human Resources Officer 48 -
Director TitleAgeSince
Director/Board Member 63 08/08/2016
Chairman 59 16/07/2013
Chairman 48 28/05/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.77%+4.48%+42.19%-40.62% 317.93Cr
-2.92%-6.82%+114.19%-9.36% 2.74TCr
-1.76%-14.01%+92.24%-12.89% 1.37TCr
-1.84%-2.90%+10.85%+16.50% 652.21Cr
-1.45%-0.04%-6.87%+27.11% 503.66Cr
-0.40%-2.81%-5.78%-36.62% 387.59Cr
+0.93%-1.87%-22.43%-48.02% 315.99Cr
+0.12%+0.87%-9.19%+61.39% 293.87Cr
Average -0.81%-0.44%+26.90%-5.31% 822.77Cr
Weighted average by Cap. -1.78%-1.59%+67.51%-6.55%
See all sector performances

Financials

2025 *2026 *
Net sales 2.77TCr 397.91Cr 340.21Cr 315.81Cr 296.19Cr 549.49Cr 36TCr 588.39Cr 3.62TCr 1.43TCr 17TCr 1.49TCr 1.46TCr 63TCr 3.09TCr 443.61Cr 379.29Cr 352.08Cr 330.2Cr 612.6Cr 41TCr 655.96Cr 4.04TCr 1.6TCr 19TCr 1.66TCr 1.63TCr 70TCr
Net income 118.05Cr 17Cr 14Cr 13Cr 13Cr 23Cr 1.55TCr 25Cr 154.41Cr 61Cr 733.86Cr 64Cr 62Cr 2.68TCr 141.46Cr 20Cr 17Cr 16Cr 15Cr 28Cr 1.86TCr 30Cr 185.03Cr 73Cr 879.39Cr 76Cr 75Cr 3.21TCr
Net Debt -183.6Cr -26Cr -23Cr -21Cr -20Cr -36Cr -2.42TCr -39Cr -240.15Cr -95Cr -1.14TCr -99Cr -97Cr -4.17TCr -251.11Cr -36Cr -31Cr -29Cr -27Cr -50Cr -3.3TCr -53Cr -328.46Cr -129.98Cr -1.56TCr -135.22Cr -132.46Cr -5.7TCr
More financial data * Estimated data
Logo DaShenLin Pharmaceutical Group Co., Ltd.
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
Employees
43,532
More about the company
Date Price Change Volume
21/26/21 19.58 ¥ +0.77% 67,42,339
20/26/20 19.43 ¥ -2.02% 81,38,456
19/26/19 19.83 ¥ +4.37% 1,30,70,120
16/26/16 19.00 ¥ +1.33% 68,16,213
15/26/15 18.75 ¥ +0.05% 47,51,052

End-of-day quote Shanghai S.E., January 21, 2026

More quotes
Trader
Investor
Global
Quality
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
19.58CNY
Average target price
23.84CNY
Spread / Average Target
+21.74%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603233 Stock